tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Nuformix Seeks US FDA Orphan Drug Designation for NXP002 in IPF
Company AnnouncementsNuformix Seeks US FDA Orphan Drug Designation for NXP002 in IPF
13d ago
Nuformix Confirms Total Voting Rights Following Share Issuance
PremiumCompany Announcements
Nuformix Confirms Total Voting Rights Following Share Issuance
3M ago
Nuformix Secures European Orphan Drug Designation for NXP002 in IPF
PremiumCompany Announcements
Nuformix Secures European Orphan Drug Designation for NXP002 in IPF
3M ago
Nuformix plc Announces Prospectus for New Share Issuance
PremiumCompany Announcements
Nuformix plc Announces Prospectus for New Share Issuance
3M ago
Nuformix Announces £210,000 Placing to Advance Fibrosis Treatment Program
PremiumCompany Announcements
Nuformix Announces £210,000 Placing to Advance Fibrosis Treatment Program
3M ago
Nuformix Showcases Promising NXP002 Data at ATS Congress 2025
PremiumCompany AnnouncementsNuformix Showcases Promising NXP002 Data at ATS Congress 2025
3M ago
Nuformix Reports Progress on NXP002 and Financial Results for H1 2025
Premium
Company Announcements
Nuformix Reports Progress on NXP002 and Financial Results for H1 2025
4M ago
Nuformix’s NXP002 Receives Positive EMA Opinion for Orphan Drug Designation
Premium
Company Announcements
Nuformix’s NXP002 Receives Positive EMA Opinion for Orphan Drug Designation
4M ago
Nuformix’s NXP002 Programme Receives Positive EMA Opinion for Orphan Drug Designation
PremiumCompany Announcements
Nuformix’s NXP002 Programme Receives Positive EMA Opinion for Orphan Drug Designation
4M ago
Nuformix Announces Office Relocation and New Company Secretary Appointment
PremiumCompany Announcements
Nuformix Announces Office Relocation and New Company Secretary Appointment
4M ago
Nuformix PLC Updates Share Admission Date and Expands Capital
PremiumCompany Announcements
Nuformix PLC Updates Share Admission Date and Expands Capital
4M ago
Nuformix Announces Exercise of Warrants and Share Issuance
PremiumCompany Announcements
Nuformix Announces Exercise of Warrants and Share Issuance
4M ago
Nuformix Reports Positive Results for NXP002 in Lung Disease Models
PremiumCompany AnnouncementsNuformix Reports Positive Results for NXP002 in Lung Disease Models
5M ago
Nuformix plc AGM Resolutions Passed with Strong Shareholder Support
Premium
Company Announcements
Nuformix plc AGM Resolutions Passed with Strong Shareholder Support
5M ago
Nuformix Updates Total Voting Rights Following Share Issuance
Premium
Company Announcements
Nuformix Updates Total Voting Rights Following Share Issuance
6M ago
Nuformix Releases 2024 Financial Report and Announces 2025 AGM
PremiumCompany Announcements
Nuformix Releases 2024 Financial Report and Announces 2025 AGM
6M ago
Nuformix Plc Announces £168,750 Placing for Strategic Development
PremiumCompany Announcements
Nuformix Plc Announces £168,750 Placing for Strategic Development
7M ago
Nuformix Advances NXP002 in Fibrosis Treatment Efforts
PremiumCompany Announcements
Nuformix Advances NXP002 in Fibrosis Treatment Efforts
7M ago
Nuformix Submits Orphan Drug Designation Application for NXP002
PremiumCompany Announcements
Nuformix Submits Orphan Drug Designation Application for NXP002
7M ago
Nuformix PLC Pursues Orphan Drug Designation for NXP002 and Explores Partnership Opportunities
PremiumCompany AnnouncementsNuformix PLC Pursues Orphan Drug Designation for NXP002 and Explores Partnership Opportunities
7M ago
Nuformix Plc Clarifies Voting Rights Amidst Share Issuance
Premium
Company Announcements
Nuformix Plc Clarifies Voting Rights Amidst Share Issuance
9M ago
Nuformix Directors Boost Stake in Fundraising Effort
Premium
Company Announcements
Nuformix Directors Boost Stake in Fundraising Effort
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >